# A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)

> **NCT04495257** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Yale University** · enrollment: 26 (actual)

## Conditions studied

- Advanced Melanoma
- Renal Cell Carcinoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab
- **DRUG:** APX005M

## Key facts

- **NCT ID:** NCT04495257
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-14
- **Primary completion:** 2026-02-28
- **Final completion:** 2026-08-28
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2025-10-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04495257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04495257, "A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04495257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*